Pharming Group (NASDAQ:PHAR - Get Free Report)'s share price traded down 3.4% on Monday . The company traded as low as $9.55 and last traded at $9.55. 455 shares were traded during mid-day trading, a decline of 91% from the average session volume of 5,137 shares. The stock had previously closed at $9.89.
Wall Street Analyst Weigh In
PHAR has been the subject of several recent research reports. Jefferies Financial Group assumed coverage on Pharming Group in a research report on Monday, December 9th. They issued a "buy" rating and a $14.00 price target for the company. Oppenheimer cut their price objective on shares of Pharming Group from $31.00 to $30.00 and set an "outperform" rating for the company in a research report on Monday, October 28th. Finally, HC Wainwright reissued a "buy" rating and issued a $37.00 price target on shares of Pharming Group in a report on Tuesday, December 17th.
View Our Latest Report on Pharming Group
Pharming Group Price Performance
The firm has a market capitalization of $688.53 million, a PE ratio of -39.04 and a beta of -0.08. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76. The business's 50 day moving average is $8.62 and its two-hundred day moving average is $8.28.
Institutional Trading of Pharming Group
A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC grew its position in shares of Pharming Group (NASDAQ:PHAR - Free Report) by 75.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 41,110 shares of the company's stock after purchasing an additional 17,675 shares during the quarter. Silverberg Bernstein Capital Management LLC owned approximately 0.06% of Pharming Group worth $339,000 as of its most recent SEC filing. 0.03% of the stock is currently owned by institutional investors and hedge funds.
Pharming Group Company Profile
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Read More
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
